Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Goodwill (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Goodwill for 14 consecutive years, with $286.3 million as the latest value for Q4 2024.

  • On a quarterly basis, Goodwill changed 0.38% to $286.3 million in Q4 2024 year-over-year; TTM through Dec 2024 was $286.3 million, a 0.38% change, with the full-year FY2024 number at $286.3 million, changed 0.38% from a year prior.
  • Goodwill was $286.3 million for Q4 2024 at Myriad Genetics, roughly flat from $287.0 million in the prior quarter.
  • In the past five years, Goodwill ranged from a high of $327.6 million in Q2 2020 to a low of $237.8 million in Q2 2022.
  • A 5-year average of $279.8 million and a median of $286.8 million in 2022 define the central range for Goodwill.
  • Peak YoY movement for Goodwill: dropped 21.48% in 2020, then rose 19.9% in 2022.
  • Myriad Genetics' Goodwill stood at $327.6 million in 2020, then decreased by 26.98% to $239.2 million in 2021, then rose by 19.9% to $286.8 million in 2022, then increased by 0.21% to $287.4 million in 2023, then decreased by 0.38% to $286.3 million in 2024.
  • Per Business Quant, the three most recent readings for MYGN's Goodwill are $286.3 million (Q4 2024), $287.0 million (Q1 2024), and $287.4 million (Q4 2023).